Latest News Archive

Please select Category, Year, and then Month to display items

UFS alumna and Council member honoured by the American Bar Association

01 July 2022 | Story Dr Nitha Ramnath | Photo Supplied

Leah Molatseli_latest news — Leah Molatseli.

Leah Molatseli– alumna and Council member of the University of the Free State (UFS) – is the first African woman to be recognised by the American Bar Association in its list of Women of Legal Tech for her contribution and influence in the legal tech industry. A commitment to diversity is one of the core values of the American Bar Association, which the Law Practice Division aims to reinforce in the legal tech sector. Annually, talented women in the legal tech space are recognised for making an impact on legal tech.

A lawyer by profession, published legal tech author and speaker, as well as legal tech and innovation specialist, Molatseli uses technology and innovative means to empower and educate law professionals. She is currently head of business development at Legal Interact, a South African law firm that provides technology solutions for the legal industry.

Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, congratulated Molatseli on her achievement. “On behalf of the executive committee of the University of the Free State (UFS) and the university community, I would like to extend my warmest congratulations on being recognised by the American Bar Association for your contribution to the legal tech industry. Being the first African woman to be honoured in this way makes this accomplishment even more extraordinary. You are a trailblazer in your field in so many ways,” said Prof Petersen.

Prof Petersen said, “The university, and the Faculty of Law in particular, is proud to be associated with you. We also appreciate your continued support to the institution. Your dedication and expertise inspire us all – I will continue to follow your professional journey, because I know there is much more in store”. Prof Petersen continued to thank Molatseli for contributing to the legal field in an innovative and contemporary manner.

Molatseli is host of and guest speaker for various legal tech talks globally, as well as a guest lecturer at the University of Cape Town, where she develops and teaches legal tech innovation-related courses to the legal industry. A Mandela Washington fellow, as well as a Notre Dame alumna, she is a member of the Women in Tech South African Chapter, a country member for the Global Legal Tech Consortium, and is one of 2022’s ILTA’s Most Influential Women in Legal Tech honourees.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children

2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept